Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PF-06865571 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

NCT03230383
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06865571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

NCT04321031
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Interventions
Placebo, PF-06865571, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
184
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

NCT04866225
View directory record Official record
Conditions
Healthy Participants
Interventions
Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Results available

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

NCT04399538
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease
Interventions
PF-06865571, PF-05221304, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
11
States / cities
Lincoln, California • Montclair, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

NCT04839393
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PF-06882961 followed by PF-06882961/PF-06865571, PF-06882961/PF-06865571 followed by PF-06882961, PF-06882961 + PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

NCT03092232
View directory record Official record
Conditions
Healthy
Interventions
PF-06865571, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06865571 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 18, 2026, 6:41 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

NCT03776175
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
PF-05221304 Monotherapy, PF-06865571 Monotherapy, Placebo, PF-05221304 and PF-06865571 Combination
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
29
States / cities
Bakersfield, California • Beverly Hills, California • Chula Vista, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 18, 2026, 6:41 AM EDT